Cartesian Therapeutics Inc (RNAC)

Currency in USD
6.930
+0.710(+11.41%)
Closed·
6.9300.000(0.00%)
·
RNAC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.2106.975
52 wk Range
5.60015.570
Key Statistics
Prev. Close
6.22
Open
6.21
Day's Range
6.21-6.975
52 wk Range
5.6-15.57
Volume
230.35K
Average Volume (3m)
202.15K
1-Year Change
-47.7953%
Book Value / Share
-5.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNAC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.571
Upside
+413.30%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cartesian Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.571
(+413.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy44.00+534.92%-MaintainMar 09, 2026
Mizuho
Buy40.00+477.20%-MaintainMar 09, 2026
Cantor Fitzgerald
Buy16.00+130.88%-UpgradeMar 09, 2026
H.C. Wainwright
Buy30.00+332.90%40.00MaintainNov 19, 2025
BTIG
Buy44.00+534.92%42.00MaintainNov 14, 2025

Earnings

Latest Release
Mar 09, 2026
EPS / Forecast
-3.56 / -1.02
Revenue / Forecast
947K / --
EPS Revisions
Last 90 days

RNAC Income Statement

Compare RNAC to Peers and Sector

Metrics to compare
RNAC
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.1x−0.5x
PEG Ratio
0.01−0.110.00
Price/Book
−1.2x2.2x2.6x
Price / LTM Sales
103.0x5.3x3.3x
Upside (Analyst Target)
-287.2%47.7%
Fair Value Upside
Unlock17.1%6.6%Unlock

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.62M9.89%16.31M
Other Institutional Investors
9.42M35.55%58.62M
Public Companies & Retail Investors
14.46M54.56%89.95M
Total
26.51M100.00%164.89M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Squarepoint OPS LLC8.34%2,209,60113,744
Squarepoint Master Fund Limited8.22%2,178,65213,551

People Also Watch

2.2270
KITT
-5.64%
16.5700
EDSA
-5.80%
7.230
SLDB
+1.40%
9.360
KPTI
+6.73%
2.265
ALLO
+5.35%

FAQ

What Is the Cartesian Therapeutics (RNAC) Stock Price Today?

The Cartesian Therapeutics stock price today is 6.930 USD.

What Stock Exchange Does Cartesian Therapeutics Trade On?

Cartesian Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cartesian Therapeutics?

The stock symbol for Cartesian Therapeutics is "RNAC."

What Is the Cartesian Therapeutics Market Cap?

As of today, Cartesian Therapeutics market cap is 204.200M USD.

What Is Cartesian Therapeutics's Earnings Per Share (TTM)?

The Cartesian Therapeutics EPS (TTM) is -5.798.

From a Technical Analysis Perspective, Is RNAC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cartesian Therapeutics Stock Split?

Cartesian Therapeutics has split 1 times.

How Many Employees Does Cartesian Therapeutics Have?

Cartesian Therapeutics has 75 employees.

What is the current trading status of Cartesian Therapeutics (RNAC)?

As of May 04, 2026, Cartesian Therapeutics (RNAC) is trading at a price of 6.930 USD, with a previous close of 6.220 USD. The stock has fluctuated within a day range of 6.210 USD to 6.975 USD, while its 52-week range spans from 5.600 USD to 15.570 USD.

What Is Cartesian Therapeutics (RNAC) Price Target According to Analysts?

The average 12-month price target for Cartesian Therapeutics is 35.571 USD, with a high estimate of 44 USD and a low estimate of 16 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +413.30% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.